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As tumors grow, they acquire mutations, some of which create neoantigens that influence the response of patients to immune checkpoint inhibitors. We explored the impact of neoantigen intratumor heterogeneity (ITH) on antitumor immunity. Through integrated analysis of ITH and neoantigen burden, we demonstrate a relationship between clonal neoantigen burden and overall survival in primary lung adenocarcinomas. CD8 + tumor-infiltrating lymphocytes reactive to clonal neoantigens were identified in early-stage non-small cell lung cancer and expressed high levels of PD-1. Sensitivity to PD-1 and CTLA-4 blockade in patients with advanced NSCLC and melanoma was enhanced in tumors enriched for clonal neoantigens. T cells recognizing clonal neoantigens were detectable in patients with durable clinical benefit. Cytotoxic chemotherapy-induced subclonal neoantigens, contributing to an increased mutational load, were enriched in certain poor responders. These data suggest that neoantigen heterogeneity may influence immune surveillance and support therapeutic developments targeting clonal neoantigens. R ecent studies have highlighted the relevance of tumor neoantigens in the recognition of cancer cells by the immune system (1-4), prompting a renewed interested in personalized vaccines and cell therapies that target cancer mutations (5, 6) . However, although genomic data are revealing the extent of genetic heterogeneity within single tumors (7), the influence of intratumor heterogeneity (ITH) upon the neoantigen landscape and sensitivity to immune modulation is unclear.
To explore neoantigen heterogeneity and its influence on antitumor immunity in earlystage non-small cell lung cancer (NSCLC), we applied a bioinformatics pipeline to seven primary NSCLCs subjected to multiregion sequence analysis (table S1) (8, 9) . In total, 2860 putative neoantigens were predicted across the cohort, with a median of 326 neoantigens predicted per tumor (range of 80 to 741) (Fig. 1A) . Neoantigen heterogeneity varied considerably, with an average of 44% neoantigens found heterogeneously, in a subset of tumor regions (range of 10 to 78%).
To address the clinical relevance of neoantigen burden and, specifically, the importance of clonal (present in all tumor cells) versus subclonal (present only in a subset) neoantigens, we subjected a predominantly early-stage cohort of 106 stage I/II, 43 stage III/IV, and 1 unknown-stage lung adenocarcinoma (LUAD) and 92 stage I/II and 32 stage III/IV lung squamous cell carcinoma (LUSC) cases from The Cancer Genome Atlas (TCGA) to neoantigen and clonality analysis (10-12) (Fig. 1B) . In this setting, to determine clonality from sequencing of a single sample, the cancer cell fraction, which describes the proportion of cancer cells harboring a mutation, was determined for each neoantigen (13) .
A high neoantigen burden, defined as the upper quartile of neoantigen load, was associated with significantly longer overall survival in LUAD (P = 0.025) (Fig. 1, C and D, and fig. S1A ), and a trend for homogeneous tumors (neoantigen ITH ≤ 1%) to have longer overall survival times as compared with that of heterogeneous tumors was also observed (P = 0.061) ( fig. S1B ). Although tumors with a high burden of neoantigens were found to be significantly more homogeneous than those with a low burden of neoantigens (P < 0.0001, Wilcoxon rank-sum test) ( fig. S1C ), a combination of neoantigen ITH and neoantigen burden (as outlined in the schematic in Fig. 1C ) was more significant than simply considering either metric alone and was observed across multiple different neoantigen ITH thresholds (without ITH threshold, P = 0.025; ITH threshold = 0, P = 0.019; ITH threshold = 0.01, P = 0.0096; ITH threshold = 0.05, P = 0.021) (Fig. 1D) , remaining significant in multivariate analysis when including the tumor stage (table S2) .
Despite a comparable range of predicted neoantigens in LUSC, no statistically significant association between overall survival and neoantigen load was observed in this subtype, even when incorporating neoantigen ITH ( fig. S2, A to D) . To investigate the reason for this disparity, we explored whether any immune-regulatory genes were differentially expressed between these two cancer types. Human lymphocyte antigen (HLA) class I genes-including HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G, as well as b 2 microglobulin (b2M), a component of the major histocompatibility complex (MHC) class I moleculewere expressed at a significantly lower level in LUSC as compared with LUAD ( fig. S3A and table S3A), and this difference was observed across all levels of neoantigen burden ( fig. S3B and table S3B). HLA class I genes were also downregulated compared with matched normal samples in LUSC (table S3C ). These data suggest that the presence of a high number of clonal neoantigens in homogeneous LUAD may favor effective immune surveillance, whereas in LUSC, immune escape may be more prevalent through HLA down-regulation.
We next evaluated whether immune-related genes were differentially expressed between homogeneous LUAD tumors (≤1% neoantigen ITH) with a high clonal neoantigen burden (greater than or equal to upper-quartile clonal neoantigens) compared with heterogeneous (>1% neoantigen ITH) or low clonal neoantigen burden tumors (less than upper-quartile clonal neoantigens). Eight genes were found to be significantly differentially expressed between these two groups (table S4A) . Programmed cell death ligand-1 (PD-L1) and the proinflammatory cytokine interleukin-6 (IL-6) were the most significantly differentially expressed genes, up-regulated in the homogeneous and high clonal neoantigen group. When we specifically compared tumors in the upper quartile of clonal neoantigen burden with tumors in the lower quartile, we identified an additional 25 significantly differentially expressed genes (table S4B and fig. S4A ). CD8A, CD8B, and genes associated with antigen presentation (TAP-1, TAP-2, and STAT-1), T cell migration (CXCL-10 and CXCL-9), and effector T cell function [interferon-g (IFN-g) and granzymes B, H, and A] were up-regulated in the high clonal neoantigen cohort and found to cluster together, indicating coexpression ( fig. S4B ). PD-1 and lymphocyte activation gene 3 (LAG-3)-negative regulators of T cell function (14)-were also identified in this cluster, as were the ligands PD-L1 and PD-L2.
These data suggest that a high clonal neoantigen burden in LUAD is associated with an inflamed tumor microenvironment enriched with activated effector T cells, potentially regulated by inhibitory immune checkpoint molecules and their ligands. We therefore attempted to identify and characterize T cells reactive to neoantigens in patients with early-stage NSCLC. We focused on two tumors, L011 and L012, with a comparable number of predicted neoantigens and a similar smoking history, but divergent levels of neoantigen ITH (8 versus 74% heterogeneous predicted neoantigens) (Fig. 2 , A to C). We used 288 and 354 putative neoantigen-loaded, HLA-matched multimers derived from L011 and L012, respectively, to screen CD8 + T cells expanded from individual tumor regions and adjacent normal lung tissue, using a previously described high-throughput method (Fig. 2 ; however, in this case, reactivity toward wild-type peptide was also observed ( fig. S5C ). The mutation in the MYADM R30W peptide lies in the anchor residue, primarily affecting HLA binding and not T cell recognition. Although the data suggest that T cells in this patient can recognize both mutant and wild-type peptides when stabilized within a MHC-multimer system, the very low predicted affinity of the wild-type peptide to HLA would be expected to prevent adequate presentation in vivo.
We next used MHC multimers that identify neoantigen-reactive T (NAR-T) cells to characterize NAR-T cells in unexpanded samples (Fig. 3 Given the potential ability of clonal neoantigens to promote priming and infiltration by neoantigen reactive T cells expressing high levels of PD-1, we explored whether response to PD-1 blockade in patients with advanced NSCLC may be influenced by neoantigen ITH. Exome sequencing data from a recent study in which 34 patients were treated with pembrolizumaban antibody targeting PD-1-was obtained (table  S5) (2) , and the clonal architecture of each tumor estimated (possible for 31 of 34 tumors).
Neoantigen burden was related to clinical response to pembrolizumab, with a high neoantigen repertoire associated with improved outcome, as previously reported (Fig. 4A) . However, consistent with the importance of clonal neoantigens, the clinical efficacy of PD-1 blockade also appeared related to the clonal architecture of each tumor (Fig. 4A) , with tumors derived from patients with no durable benefit [defined as in (2)] exhibiting significantly higher neoantigen ITH than that of tumors from patients with a durable clinical benefit (P = 0.006, Wilcoxon rank sum (Y2087 and SB10944). For example, despite a large neoantigen burden, ZA6505 exhibited progressive disease, relapsing after 2 months. ZA6505 was one of the most heterogeneous tumors within the cohort, with over 80% of mutations classified as subclonal.
Tumors with both a high clonal neoantigen burden and low neoantigen ITH were associated with significantly longer progression-free survival, and this relationship remained robust to the choice of ITH threshold, with lower hazard ratios observed as compared with the use of neoantigen burden alone (Fig. 4B) . The majority of clonal neoantigens could be attributed to smokinginduced mutations (Fig. 4A) . Greater PD-L1 expression was observed in tumors harboring a large clonal neoantigen burden and low neoantigen heterogeneity compared with the remaining tumors (P = 0.0017, c 2 test) ( Fig. 4A and fig. S6 ). Next, we obtained data from 64 melanoma patients treated with either ipilimumab or tremelimumab, which are antibodies against CTLA-4 (4). Clonal architecture analysis was possible for 57 of 64 tumors, and significantly improved overall survival was observed in tumors exhibiting a low neoantigen ITH and a high clonal neoantigen burden. This relationship was observed when multiple different ITH thresholds were used, similar to the NSCLC cohort (ITH threshold = 0.01, P = 0.008; ITH threshold = 0.02, P = 0.011; ITH threshold = 0.05, P = 0.083) (Fig. 4C) . The relationship between neoantigen burden and survival outcome was not statistically significant without an ITH threshold (P = 0.083) (Fig. 4C) .
To address whether radiation or cytotoxic exposure might stimulate production of subclonal neoantigens that could contribute to total neoantigen burden but not the efficacy of checkpoint blockade, sequencing data from a more heavily pretreated melanoma cohort, comprising 110 tumors, were obtained (17) . For the subset of tumors for which clonal analysis was possible (78 of 110 tumors, a smaller and less adequately powered cohort as compared with the published analysis), total neoantigen burden was not significantly associated with efficacy of immune checkpoint inhibition [classified as in (17)], although a trend was observed (P = 0.24, Wilcoxon rank sum test) ( fig. S7A ). However, an enrichment for tumors exhibiting high neoantigen heterogeneity or low clonal neoantigen burden (both stratified according to the median of the cohort) reached borderline significance in patients with minimal or no benefit compared with patients exhibiting a clinical benefit (P = 0.06, Fisher's exact test). Neoantigen burden was not found to be significantly associated with overall survival in this cohort ( fig. S7B) . Two of the most heterogeneous tumors (Pat58 and Pat151) with minimal or no benefit were among those treated with the alkylating agent dacarbazine (DTIC) before anti-CTLA therapy, and for both, >98% of subclonal mutations were attributable to mutational Signature 11, a signature associated with prior exposure to alkylating agents (18, 19) . One patient with stable disease-Pat80, who was also treated with DTIC before anti-CTLA-4 therapyalso harbored an increase in Signature 11 and progressed by 6 months [classified as no durable benefit according to (2) ]. These data suggest that therapy may induce subclonal mutations that fail to drive an efficient antitumor response, although further data are needed to confirm this observation. and (E), with size of symbol increasing with frequency.
Last, we reasoned that T cells recognizing clonal antigens should be detectable in patients deriving favorable responses to checkpoint blockade. Previous analysis of peripheral blood lymphocytes (PBLs) from CA9903, a LUAD patient with an exceptional response to pembrolizumab, identified a CD8 + T cell population in autologous PBLs, recognizing a predicted neoantigen resulting from a HERC1 P3278S mutation (ASNASSAAK) (2) . Consistent with the relevance of clonal neoantigens, this mutation was found to be present in 100% of cancer cells within the sequenced tumor (Fig. 4D) . Similarly, analysis of peripheral blood mononuclear cells (PBMCs) from the patients with CR9309 and CR0095-melanomas that responded to anti-CTLA-4 therapy, resulting in prolonged patient survival-identified CD8 + T cell populations, recognizing tumor-specific neoantigens (4). In both cases, the neoantigens linked to a T cell response were derived from clonal mutations, predicted to be present in 100% of cancer cells (Fig. 4, E and F) .
Previous studies have reported that neoantigen burden influences sensitivity to immune checkpoint blockade in NSCLC and melanoma (2, 4, 17) . However, the influence of ITH on this relationship has not been investigated. Our results, although limited by access to small and diverse patient cohorts and single-site biopsy data that likely overestimate the number of clonal mutations, suggest that clonal and subclonal neoantigens do not drive equally effective antitumor immunity. Indeed, using the described approach, despite screening more than 250 peptides against putative subclonal neoantigens, we were only able to detect T cells that recognize clonal neoantigens. Conceivably, higher-neoantigen ITH may result in lower antigen dosage as compared with homogeneous tumors with high clonal neoantigen burden, thus reducing the chances of identifying T cells reactive to subclonal neoantigens. Furthermore, in cases in which T cells reactive to subclonal neoantigens are generated, these will be unable to target all tumor cells, limiting overall tumor control.
The observation that certain anti-CTLA-4 refractory tumors were enriched for subclonal mutations caused by alkylating agents suggests that mutations induced by therapy may enhance total neoantigen burden but might not elicit an effective antitumor response, possibly because of the subclonal nature of the neoantigens that results from cytotoxic exposure. These results highlight the need to consider both the antitumor effects of alkylating agents as well as the potential risk of inducing subclonal mutations (19) .
The identification of cytotoxic tumor-infiltrating T cells that recognize clonal mutations, shared by all tumor cells, might hold promise for adoptive therapy strategies to address the challenges of ITH (20) . The extensive clonal mutational repertoire present in smoking-associated NSCLC (8, 21) could render this disease vulnerable to vaccination or T cell therapies targeting multiple clonal neoantigens, in combination with appropriate immune checkpoint modulation. HE3202  SA9755  CA9903  DI6359  SC0899  FR9547  M4945  KA3947  RI1933  SC6470  AL4602  RH090935  Y2087  SB010944  TU0428  ZA6505  CU9061  MA7027  R7495  DM123062  RO3338  JB112852  WA7899  LO3793  GR4788  LO5004  NI9507  SR070761  BL3403 
